Share Price and Basic Stock Data
Last Updated: December 25, 2025, 2:42 am
| PEG Ratio | 3.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
J B Chemicals & Pharmaceuticals Ltd operates in the pharmaceuticals sector, reporting a market capitalization of ₹28,440 Cr and a current stock price of ₹1,816. The company has demonstrated robust revenue growth, with sales increasing from ₹2,424 Cr in FY 2022 to ₹3,149 Cr in FY 2023, and further to ₹3,484 Cr in FY 2024. The trailing twelve months (TTM) sales reached ₹4,092 Cr, indicating a strong upward trajectory. Quarterly sales figures for Jun 2023 stood at ₹896 Cr and rose to ₹1,004 Cr by Jun 2024, reflecting a consistent demand for its products. Despite fluctuations in quarterly sales, the overall trend indicates resilience and adaptability in a competitive market. The company’s ability to generate revenue growth aligns with the broader industry trends, which have shown a positive outlook due to increasing healthcare needs and a growing pharmaceutical market in India.
Profitability and Efficiency Metrics
J B Chemicals reported a net profit of ₹718 Cr, reflecting a net profit margin of 16.83%, which is favorable compared to typical sector norms. The company’s operating profit margin (OPM) stood at 26% for FY 2024, indicating effective cost management and operational efficiency. Quarterly OPM figures for Jun 2024 reached 28%, showcasing strong profitability in the latest reporting period. The return on equity (ROE) was reported at 20.1%, and return on capital employed (ROCE) at 25.8%, both of which are commendable and suggest efficient utilization of equity and capital. Furthermore, the interest coverage ratio (ICR) was exceptionally high at 91.24, indicating a strong capacity to meet interest obligations, which underscores financial health and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of J B Chemicals reflects significant strength, with total assets reported at ₹4,265 Cr and total liabilities at ₹4,265 Cr, indicating a well-managed capital structure. The company reported reserves of ₹3,790 Cr, a substantial increase from ₹2,465 Cr in FY 2023, which enhances its financial stability and potential for future growth. Notably, borrowings are minimal, recorded at just ₹19 Cr, contributing to a debt-to-equity ratio of 0.00, which is exceptionally strong and well below industry averages. This low leverage position allows the company to pursue expansion opportunities without the burden of high debt. Additionally, the current ratio stood at 3.04 and the quick ratio at 2.20, both indicating strong liquidity positions, ensuring that the company can cover short-term obligations comfortably.
Shareholding Pattern and Investor Confidence
As of September 2025, the shareholding pattern of J B Chemicals reveals a diversified ownership structure. Promoters hold 47.56% of the company, a notable decline from 53.95% in December 2022, suggesting a gradual dilution of promoter shareholding. Foreign institutional investors (FIIs) accounted for 15.31%, a decrease from 18.30% in March 2025, while domestic institutional investors (DIIs) have increased their stake to 22.83%, indicating growing confidence among domestic investors. The public shareholding stands at 14.31%, reflecting active retail participation. The total number of shareholders has increased to 71,957, underscoring an expanding investor base and increased interest in the company’s performance. This diverse ownership may enhance governance and strategic decision-making, contributing positively to long-term shareholder value.
Outlook, Risks, and Final Insight
The outlook for J B Chemicals appears promising, bolstered by strong revenue growth and sound financial health. However, the company faces risks such as potential regulatory changes in the pharmaceutical sector, which could impact operational efficiency and profitability. Additionally, fluctuations in raw material prices could pressure margins. The decreasing promoter stake might raise concerns regarding long-term commitment, although the rising share of DIIs indicates positive institutional sentiment. In a scenario of sustained demand for pharmaceutical products and effective cost management, the company is well-positioned for growth. Conversely, any adverse regulatory developments or significant shifts in market dynamics could pose challenges. Overall, J B Chemicals stands as a resilient player in the pharmaceutical landscape, with solid fundamentals supporting its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,770 Cr. | 438 | 479/192 | 98.8 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,181.97 Cr | 1,153.40 | 53.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of J B Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 785 | 809 | 793 | 762 | 896 | 882 | 845 | 862 | 1,004 | 1,001 | 963 | 949 | 1,094 |
| Expenses | 612 | 625 | 618 | 599 | 664 | 638 | 621 | 664 | 724 | 730 | 709 | 723 | 793 |
| Operating Profit | 173 | 185 | 175 | 164 | 232 | 244 | 223 | 198 | 280 | 271 | 255 | 226 | 301 |
| OPM % | 22% | 23% | 22% | 21% | 26% | 28% | 26% | 23% | 28% | 27% | 26% | 24% | 28% |
| Other Income | 1 | 1 | 3 | 5 | 6 | 8 | 7 | 17 | 6 | 10 | 8 | 14 | 15 |
| Interest | 6 | 8 | 8 | 14 | 12 | 10 | 12 | 9 | 6 | 2 | 3 | 1 | 1 |
| Depreciation | 26 | 28 | 28 | 32 | 31 | 32 | 34 | 41 | 41 | 42 | 42 | 46 | 43 |
| Profit before tax | 142 | 150 | 141 | 122 | 194 | 209 | 184 | 165 | 240 | 237 | 218 | 193 | 272 |
| Tax % | 26% | 26% | 25% | 28% | 27% | 28% | 27% | 23% | 26% | 26% | 25% | 25% | 25% |
| Net Profit | 105 | 111 | 106 | 88 | 142 | 151 | 134 | 126 | 177 | 175 | 162 | 146 | 202 |
| EPS in Rs | 6.79 | 7.18 | 6.86 | 5.66 | 9.19 | 9.72 | 8.61 | 8.13 | 11.39 | 11.24 | 10.45 | 9.36 | 12.97 |
Last Updated: August 1, 2025, 6:55 pm
Below is a detailed analysis of the quarterly data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,094.00 Cr.. The value appears strong and on an upward trend. It has increased from 949.00 Cr. (Mar 2025) to 1,094.00 Cr., marking an increase of 145.00 Cr..
- For Expenses, as of Jun 2025, the value is 793.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 723.00 Cr. (Mar 2025) to 793.00 Cr., marking an increase of 70.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 301.00 Cr.. The value appears strong and on an upward trend. It has increased from 226.00 Cr. (Mar 2025) to 301.00 Cr., marking an increase of 75.00 Cr..
- For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 24.00% (Mar 2025) to 28.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 43.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 46.00 Cr. (Mar 2025) to 43.00 Cr., marking a decrease of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 272.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 272.00 Cr., marking an increase of 79.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00%.
- For Net Profit, as of Jun 2025, the value is 202.00 Cr.. The value appears strong and on an upward trend. It has increased from 146.00 Cr. (Mar 2025) to 202.00 Cr., marking an increase of 56.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 12.97. The value appears strong and on an upward trend. It has increased from 9.36 (Mar 2025) to 12.97, marking an increase of 3.61.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,022 | 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,484 | 3,918 | 4,092 |
| Expenses | 874 | 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | 2,587 | 2,886 | 3,000 |
| Operating Profit | 148 | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 897 | 1,032 | 1,091 |
| OPM % | 14% | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% | 26% | 26% | 27% |
| Other Income | -27 | 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 37 | 38 | 52 |
| Interest | 6 | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 44 | 12 | 6 |
| Depreciation | 28 | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 138 | 171 | 176 |
| Profit before tax | 87 | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 887 | 962 |
| Tax % | 30% | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% | 26% | 26% | |
| Net Profit | 62 | 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 718 |
| EPS in Rs | 3.63 | 5.92 | 9.58 | 10.85 | 8.28 | 12.05 | 17.60 | 28.98 | 24.93 | 26.48 | 35.61 | 42.37 | 46.05 |
| Dividend Payout % | 41% | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% | 34% | 37% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 61.29% | 63.00% | 12.88% | -24.46% | 39.57% | 40.21% | 65.07% | -14.03% | 6.22% | 34.88% | 19.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -50.12% | -37.34% | 64.02% | 0.64% | 24.87% | -79.10% | 20.25% | 28.66% | -15.53% |
J B Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 20% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 34% |
| 3 Years: | 23% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| Last Year: | 20% |
Last Updated: September 5, 2025, 8:10 am
Balance Sheet
Last Updated: December 4, 2025, 1:28 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
| Reserves | 1,026 | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 | 3,418 | 3,790 |
| Borrowings | 93 | 127 | 193 | 49 | 29 | 26 | 29 | 45 | 55 | 572 | 378 | 28 | 19 |
| Other Liabilities | 215 | 365 | 270 | 262 | 294 | 286 | 349 | 376 | 412 | 495 | 687 | 804 | 887 |
| Total Liabilities | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,265 | 4,712 |
| Fixed Assets | 311 | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 | 1,968 | 1,977 |
| CWIP | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 63 | 32 |
| Investments | 500 | 552 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 | 345 | 519 |
| Other Assets | 494 | 552 | 594 | 580 | 674 | 699 | 743 | 894 | 1,293 | 1,385 | 1,519 | 1,889 | 2,184 |
| Total Assets | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,265 | 4,712 |
Below is a detailed analysis of the balance sheet data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,790.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,418.00 Cr. (Mar 2025) to 3,790.00 Cr., marking an increase of 372.00 Cr..
- For Borrowings, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 28.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 887.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 804.00 Cr. (Mar 2025) to 887.00 Cr., marking an increase of 83.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,712.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,265.00 Cr. (Mar 2025) to 4,712.00 Cr., marking an increase of 447.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,977.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,968.00 Cr. (Mar 2025) to 1,977.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 31.00 Cr..
- For Investments, as of Sep 2025, the value is 519.00 Cr.. The value appears strong and on an upward trend. It has increased from 345.00 Cr. (Mar 2025) to 519.00 Cr., marking an increase of 174.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,184.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,889.00 Cr. (Mar 2025) to 2,184.00 Cr., marking an increase of 295.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,712.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,265.00 Cr. (Mar 2025) to 4,712.00 Cr., marking an increase of 447.00 Cr..
Notably, the Reserves (3,790.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 55.00 | 53.00 | 13.00 | 183.00 | 189.00 | 280.00 | 349.00 | 515.00 | 488.00 | 124.00 | 519.00 | -27.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84 | 84 | 82 | 72 | 78 | 68 | 71 | 70 | 84 | 67 | 72 | 76 |
| Inventory Days | 120 | 122 | 146 | 138 | 145 | 149 | 159 | 181 | 178 | 134 | 155 | 147 |
| Days Payable | 54 | 63 | 71 | 68 | 75 | 72 | 97 | 97 | 97 | 75 | 110 | 114 |
| Cash Conversion Cycle | 150 | 143 | 158 | 142 | 148 | 146 | 133 | 153 | 164 | 127 | 117 | 109 |
| Working Capital Days | 70 | 16 | 38 | 75 | 93 | 91 | 81 | 91 | 122 | 81 | 55 | 79 |
| ROCE % | 13% | 13% | 15% | 14% | 11% | 18% | 23% | 33% | 23% | 22% | 25% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Midcap Fund | 4,816,878 | 1.41 | 853.21 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,984,782 | 1.98 | 528.69 | 2,207,475 | 2025-12-08 05:55:37 | 35.21% |
| Franklin India Small Cap Fund | 1,448,723 | 1.9 | 256.61 | N/A | N/A | N/A |
| Canara Robeco Small Cap Fund | 1,353,805 | 1.84 | 239.8 | 790,068 | 2025-12-08 05:55:37 | 71.35% |
| Kotak Small Cap Fund | 1,296,204 | 1.32 | 229.6 | N/A | N/A | N/A |
| Axis ELSS Tax Saver Fund | 1,087,630 | 0.55 | 192.65 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 999,649 | 2.09 | 177.07 | 1,486,868 | 2025-12-08 04:19:42 | -32.77% |
| Nippon India Small Cap Fund | 991,107 | 0.26 | 175.55 | 937,872 | 2025-12-08 05:55:37 | 5.68% |
| Axis Midcap Fund | 984,875 | 0.54 | 174.45 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 898,827 | 0.32 | 159.21 | 949,834 | 2025-12-15 04:02:53 | -5.37% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 42.45 | 35.66 | 53.00 | 49.86 | 57.96 |
| Diluted EPS (Rs.) | 41.56 | 34.85 | 52.34 | 49.86 | 57.96 |
| Cash EPS (Rs.) | 53.36 | 44.52 | 67.77 | 59.35 | 66.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 220.54 | 188.36 | 320.55 | 276.73 | 234.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 220.54 | 188.36 | 320.55 | 276.73 | 234.65 |
| Revenue From Operations / Share (Rs.) | 251.67 | 224.50 | 407.00 | 313.69 | 264.29 |
| PBDIT / Share (Rs.) | 68.74 | 60.19 | 91.20 | 75.40 | 87.06 |
| PBIT / Share (Rs.) | 57.76 | 51.28 | 76.42 | 66.00 | 78.17 |
| PBT / Share (Rs.) | 57.00 | 48.42 | 71.76 | 65.33 | 77.23 |
| Net Profit / Share (Rs.) | 42.37 | 35.61 | 52.99 | 49.95 | 58.04 |
| NP After MI And SOA / Share (Rs.) | 42.37 | 35.61 | 52.97 | 49.86 | 57.96 |
| PBDIT Margin (%) | 27.31 | 26.81 | 22.40 | 24.03 | 32.93 |
| PBIT Margin (%) | 22.94 | 22.84 | 18.77 | 21.03 | 29.57 |
| PBT Margin (%) | 22.64 | 21.56 | 17.63 | 20.82 | 29.22 |
| Net Profit Margin (%) | 16.83 | 15.86 | 13.01 | 15.92 | 21.95 |
| NP After MI And SOA Margin (%) | 16.83 | 15.86 | 13.01 | 15.89 | 21.93 |
| Return on Networth / Equity (%) | 19.21 | 18.90 | 16.52 | 18.05 | 24.75 |
| Return on Capital Employeed (%) | 24.69 | 25.45 | 19.71 | 22.93 | 31.91 |
| Return On Assets (%) | 15.43 | 13.83 | 11.53 | 14.77 | 20.01 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.15 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.12 | 0.22 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.94 | 0.92 | 1.02 | 0.91 | 0.94 |
| Current Ratio (X) | 3.04 | 2.13 | 2.76 | 3.32 | 4.50 |
| Quick Ratio (X) | 2.20 | 1.56 | 1.98 | 2.25 | 3.49 |
| Inventory Turnover Ratio (X) | 7.60 | 1.75 | 1.87 | 1.73 | 1.96 |
| Dividend Payout Ratio (NP) (%) | 35.93 | 28.40 | 31.13 | 33.09 | 16.38 |
| Dividend Payout Ratio (CP) (%) | 28.53 | 22.72 | 24.33 | 27.84 | 14.21 |
| Earning Retention Ratio (%) | 64.07 | 71.60 | 68.87 | 66.91 | 83.62 |
| Cash Earning Retention Ratio (%) | 71.47 | 77.28 | 75.67 | 72.16 | 85.79 |
| Interest Coverage Ratio (X) | 91.24 | 21.07 | 19.57 | 113.79 | 92.91 |
| Interest Coverage Ratio (Post Tax) (X) | 57.24 | 13.47 | 12.37 | 76.39 | 62.94 |
| Enterprise Value (Cr.) | 25138.28 | 25860.24 | 15719.76 | 12145.74 | 9693.57 |
| EV / Net Operating Revenue (X) | 6.42 | 7.42 | 4.99 | 5.01 | 4.75 |
| EV / EBITDA (X) | 23.49 | 27.68 | 22.28 | 20.84 | 14.41 |
| MarketCap / Net Operating Revenue (X) | 6.45 | 7.35 | 4.84 | 5.02 | 4.74 |
| Retention Ratios (%) | 64.06 | 71.59 | 68.86 | 66.90 | 83.61 |
| Price / BV (X) | 7.36 | 8.76 | 6.15 | 5.70 | 5.35 |
| Price / Net Operating Revenue (X) | 6.45 | 7.35 | 4.84 | 5.02 | 4.74 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 |
After reviewing the key financial ratios for J B Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.45. This value is within the healthy range. It has increased from 35.66 (Mar 24) to 42.45, marking an increase of 6.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 41.56. This value is within the healthy range. It has increased from 34.85 (Mar 24) to 41.56, marking an increase of 6.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.36. This value is within the healthy range. It has increased from 44.52 (Mar 24) to 53.36, marking an increase of 8.84.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 220.54. It has increased from 188.36 (Mar 24) to 220.54, marking an increase of 32.18.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 220.54. It has increased from 188.36 (Mar 24) to 220.54, marking an increase of 32.18.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 251.67. It has increased from 224.50 (Mar 24) to 251.67, marking an increase of 27.17.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 68.74. This value is within the healthy range. It has increased from 60.19 (Mar 24) to 68.74, marking an increase of 8.55.
- For PBIT / Share (Rs.), as of Mar 25, the value is 57.76. This value is within the healthy range. It has increased from 51.28 (Mar 24) to 57.76, marking an increase of 6.48.
- For PBT / Share (Rs.), as of Mar 25, the value is 57.00. This value is within the healthy range. It has increased from 48.42 (Mar 24) to 57.00, marking an increase of 8.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.37. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 42.37, marking an increase of 6.76.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.37. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 42.37, marking an increase of 6.76.
- For PBDIT Margin (%), as of Mar 25, the value is 27.31. This value is within the healthy range. It has increased from 26.81 (Mar 24) to 27.31, marking an increase of 0.50.
- For PBIT Margin (%), as of Mar 25, the value is 22.94. This value exceeds the healthy maximum of 20. It has increased from 22.84 (Mar 24) to 22.94, marking an increase of 0.10.
- For PBT Margin (%), as of Mar 25, the value is 22.64. This value is within the healthy range. It has increased from 21.56 (Mar 24) to 22.64, marking an increase of 1.08.
- For Net Profit Margin (%), as of Mar 25, the value is 16.83. This value exceeds the healthy maximum of 10. It has increased from 15.86 (Mar 24) to 16.83, marking an increase of 0.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.83. This value is within the healthy range. It has increased from 15.86 (Mar 24) to 16.83, marking an increase of 0.97.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has increased from 18.90 (Mar 24) to 19.21, marking an increase of 0.31.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 25.45 (Mar 24) to 24.69, marking a decrease of 0.76.
- For Return On Assets (%), as of Mar 25, the value is 15.43. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 15.43, marking an increase of 1.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.12 (Mar 24) to 0.00, marking a decrease of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has increased from 0.92 (Mar 24) to 0.94, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.04, marking an increase of 0.91.
- For Quick Ratio (X), as of Mar 25, the value is 2.20. This value exceeds the healthy maximum of 2. It has increased from 1.56 (Mar 24) to 2.20, marking an increase of 0.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 7.60, marking an increase of 5.85.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 35.93. This value is within the healthy range. It has increased from 28.40 (Mar 24) to 35.93, marking an increase of 7.53.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from 22.72 (Mar 24) to 28.53, marking an increase of 5.81.
- For Earning Retention Ratio (%), as of Mar 25, the value is 64.07. This value is within the healthy range. It has decreased from 71.60 (Mar 24) to 64.07, marking a decrease of 7.53.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.47. This value exceeds the healthy maximum of 70. It has decreased from 77.28 (Mar 24) to 71.47, marking a decrease of 5.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 91.24. This value is within the healthy range. It has increased from 21.07 (Mar 24) to 91.24, marking an increase of 70.17.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 57.24. This value is within the healthy range. It has increased from 13.47 (Mar 24) to 57.24, marking an increase of 43.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25,138.28. It has decreased from 25,860.24 (Mar 24) to 25,138.28, marking a decrease of 721.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.42. This value exceeds the healthy maximum of 3. It has decreased from 7.42 (Mar 24) to 6.42, marking a decrease of 1.00.
- For EV / EBITDA (X), as of Mar 25, the value is 23.49. This value exceeds the healthy maximum of 15. It has decreased from 27.68 (Mar 24) to 23.49, marking a decrease of 4.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.45. This value exceeds the healthy maximum of 3. It has decreased from 7.35 (Mar 24) to 6.45, marking a decrease of 0.90.
- For Retention Ratios (%), as of Mar 25, the value is 64.06. This value is within the healthy range. It has decreased from 71.59 (Mar 24) to 64.06, marking a decrease of 7.53.
- For Price / BV (X), as of Mar 25, the value is 7.36. This value exceeds the healthy maximum of 3. It has decreased from 8.76 (Mar 24) to 7.36, marking a decrease of 1.40.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.45. This value exceeds the healthy maximum of 3. It has decreased from 7.35 (Mar 24) to 6.45, marking a decrease of 0.90.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in J B Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 16.83%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.69% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.21% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 57.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.2
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 39.6 (Industry average Stock P/E: 53.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.83%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Neelam Centre, 'B' Wing, 4th floor, Mumbai Maharashtra 400030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Duggal | Chairman & Ind.Director |
| Mr. Nikhil Chopra | WholeTime Director & CEO |
| Mr. Prashant Kumar | Non Executive Director |
| Mr. Gaurav Trehan | Non Executive Director |
| Mr. Akshay Tanna | Non Executive Director |
| Mr. Sumit Bose | Independent Director |
| Ms. Padmini Khare Kaicker | Independent Director |
| Mr. Ashwani Kumar Puri | Independent Director |
FAQ
What is the intrinsic value of J B Chemicals & Pharmaceuticals Ltd?
J B Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 25 December 2025) is 1560.50 which is 14.07% lower the current market price of 1,816.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 28,440 Cr. market cap, FY2025-2026 high/low of 1,918/1,303, reserves of ₹3,790 Cr, and liabilities of 4,712 Cr.
What is the Market Cap of J B Chemicals & Pharmaceuticals Ltd?
The Market Cap of J B Chemicals & Pharmaceuticals Ltd is 28,440 Cr..
What is the current Stock Price of J B Chemicals & Pharmaceuticals Ltd as on 25 December 2025?
The current stock price of J B Chemicals & Pharmaceuticals Ltd as on 25 December 2025 is 1,816.
What is the High / Low of J B Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of J B Chemicals & Pharmaceuticals Ltd stocks is 1,918/1,303.
What is the Stock P/E of J B Chemicals & Pharmaceuticals Ltd?
The Stock P/E of J B Chemicals & Pharmaceuticals Ltd is 39.6.
What is the Book Value of J B Chemicals & Pharmaceuticals Ltd?
The Book Value of J B Chemicals & Pharmaceuticals Ltd is 243.
What is the Dividend Yield of J B Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of J B Chemicals & Pharmaceuticals Ltd is 0.85 %.
What is the ROCE of J B Chemicals & Pharmaceuticals Ltd?
The ROCE of J B Chemicals & Pharmaceuticals Ltd is 25.8 %.
What is the ROE of J B Chemicals & Pharmaceuticals Ltd?
The ROE of J B Chemicals & Pharmaceuticals Ltd is 20.1 %.
What is the Face Value of J B Chemicals & Pharmaceuticals Ltd?
The Face Value of J B Chemicals & Pharmaceuticals Ltd is 1.00.